One research firm guiding every industry we serve
BioNixus began in pharmaceutical and healthcare research in 2012 and still leads there. The same sampling discipline and senior-led analysis now run across three connected segments — pharma & healthcare, B2B, and B2C — for clients across the Americas, EMEA, and the GCC.
The site is built as two linked silos: a regulated healthcare silo and a non-healthcare industries silo. This hub is the bridge between them.
Coverage at a glance
Three connected research segments
Pick the segment that matches your decision and go straight to the depth you need. Each one runs to the same standard BioNixus built in healthcare.
Pharma & Healthcare
Where BioNixus was built — and still leads.Pharmaceutical and healthcare research is the discipline BioNixus was founded on in 2012, and it remains the core of the firm. Everything else we do in B2B and B2C markets borrows the standards we set here: verified respondents, defensible sampling, and evidence built for a decision rather than a slide library.
Enter Pharma & Healthcare →B2B Industries
Enterprise, institutional, and infrastructure markets.B2B decisions turn on a small number of high-value buyers, long sales cycles, and committees rather than crowds. BioNixus brings the same sampling discipline and senior-led analysis we built in healthcare to technology, energy, real estate, public sector, and education research.
Enter B2B Industries →B2C Industries
Consumer demand, brands, and the shopper journey.Consumer markets move on perception, habit, and price sensitivity at scale. BioNixus measures what drives choice — across FMCG, retail, financial services, telecom, automotive, hospitality, and media — with samples that represent the real population, not an open-internet opt-in pool.
Enter B2C Industries →The Americas, EMEA, and the GCC — under one evidence framework
BioNixus is US-headquartered in Sheridan, Wyoming, with research operations in London and Cairo. That structure lets us run American and European programmes to the same standard as our MENA fieldwork — and benchmark a launch or a brand across all three regions inside a single evidence framework.
In the United States and the wider Americas, our healthcare heritage means studies are held to clinical-grade governance: verified respondents, defensible sampling, and analysis built for a decision rather than a slide library. Those same standards now carry into our B2B industries and B2C industries work, and connect back to the healthcare market research hub where the firm began.
Keep exploring
Frequently asked questions
What industries does BioNixus cover?
BioNixus organises its work into three segments: pharma & healthcare (pharma, MedTech, hospitals, biotech, and consumer health), B2B (technology, energy, real estate, public sector, and education), and B2C (FMCG, retail, automotive, hospitality, media, telecom, and financial services).
Does BioNixus only do healthcare market research?
No. Healthcare and pharmaceutical research is where BioNixus was founded and where it leads, but the same sampling discipline and senior-led analysis now extend to B2B and B2C categories through the B2B industries and B2C industries sections.
Where is BioNixus based and which regions does it cover?
BioNixus is US-headquartered in Sheridan, Wyoming, with research operations in London and Cairo. That footprint supports programmes across the Americas, Europe, and the GCC under one evidence framework, with bilingual Arabic–English fieldwork in MENA.
How are the three industry segments connected?
This hub is the deliberate bridge between them. The pharma & healthcare silo links to deep country and therapy coverage, while the B2B and B2C sections apply the same standards to non-healthcare categories. Use the segment cards above to enter the section you need.
Plan your next study with BioNixus
Tell us the decision in front of you. We will scope the evidence to match it.